Skip to main content
. Author manuscript; available in PMC: 2021 Jun 4.
Published in final edited form as: World J Urol. 2018 May 2;36(10):1621–1627. doi: 10.1007/s00345-018-2299-2

Table 3.

Clinical outcomes according to pathology at re-TUR in 934 patients.

Residual tumour at re-TUR Recurrence N (%) Progression N (%) CSM N (%)
No residual tumour (267 patients) 112 (41.9) 38 (14.2) 16 ( 6.0)
Ta tumour (378 patients) 193 (51.1) 55 (14.6) 31 ( 8.2)
T1 tumour (289 patients) 207 (71.6) 73 (25.3) 38 (13.1)
Total (934 patients) 512 (54.8) 166 (17.8) 85 (9.1)
P value P < 0.001 P < 0.001 P = 0.01